Sugi Predict

Sugi Predict / Compounds / SCHEMBL2942835

SCHEMBL2942835

SCHEMBL2942835

O=C(Nc1ccccc1)c1cnccc1CN1CC(=O)N(c2ccc(S(=O)(=O)C(F)(F)F)cc2)C1=O

nearest known ligand 0.41

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ RXFP1 Q9HBX9 2/20 0.41
▸ NAMPT P43490 1/20 0.39
▸ IGF1R P08069 2/20 0.38
▸ KDR P35968 7/20 0.37
▸ FLT1 P17948 6/20 0.37
▸ TRPV1 Q8NER1 2/20 0.37
▸ ENPP2 Q13822 2/20 0.36
▸ LMNA P02545 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ KMT2A Q03164 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2936312 0.89 RXFP1 (0.39) RXFP1NAMPTIGF1RKDRFLT1
SCHEMBL2931316 0.88 IGF1R (0.39) RXFP1NAMPTIGF1RENPP2LMNA
SCHEMBL2938114 0.88 IGF1R (0.39) NAMPTIGF1RENPP2LMNAKDM4E
SCHEMBL2933936 0.88 NAMPT (0.42) RXFP1NAMPTIGF1RTRPV1ENPP2
SCHEMBL2939402 0.86 KDR (0.46) NAMPTKDRFLT1L3MBTL1SMN1; SMN2
SCHEMBL2942229 0.86 NPC1 (0.40) NAMPTIGF1RKDRFLT1TRPV1
SCHEMBL2937085 0.85 IGF1R (0.38) NAMPTIGF1RENPP2LMNASMN1; SMN2
SCHEMBL2941066 0.85 IGF1R (0.38) RXFP1NAMPTIGF1RENPP2
SCHEMBL2939214 0.85 IGF1R (0.38) RXFP1NAMPTIGF1RENPP2LMNA
SCHEMBL2941150 0.84 PTGS1 (0.42) RXFP1NAMPTIGF1RENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 — — US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 — — EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 — — US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 — — US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 RXFP1 2972/4885NAMPT 1562/4885IGF1R 1595/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA RXFP1 2467/4885NAMPT 1795/4885IGF1R 962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.